Alliance for Pandemic Preparedness

January 28, 2021

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19



Keywords (Tags):

[Pre-print, not peer-reviewed] In a randomized, double-blinded, placebo-controlled trial (n=4,159), the anti-inflammatory medication colchicine reduced the rate of COVID-19-associated hospitalization or death among high-risk participants with COVID-19 who were not yet hospitalized. Participants who received colchicine for 30 days experienced 25% lower odds of hospitalization (95% CI 0.57-0.99), but not statistically significant lower odds for mechanical ventilation (OR=0.5, 95% CI 0.23-1.07), and death (OR=0.56, 95% CI 0.19-1.66) compared to those who received placebo. Serious adverse events were less frequent in the colchicine group (4.9% vs 6.3%), though diarrhea was more likely (13.7% vs 7.3%).

Tardif et al. (Jan 27, 2021). Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Pre-print downloaded Jan 28 from